Dianthus Therapeutics, Inc. (DNTH)

NASDAQ: DNTH · USD

$82.2

+2.67 (+3.4%)· Recorded snapshot

Market cap	4.6B
Revenue (ttm)	1.9M
Net income (ttm)	-192.2M
EPS (ttm)	-$4.11
Shares out	55.9M
Volume	461,487
Beta	0.18

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 1.9M
Net income (ttm): -192.2M
EPS (ttm): -$4.11
Market cap: 4.6B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Aanhouden

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-26.1

P25 n/aP50 n/aP75 n/a

ROIC-18.4

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All DNTH indicators

Market & fundamental data

Available fields

192

Groups with data

Currency

USD

Showing 192 of 192 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001690585
Company name	Dianthus Therapeutics, Inc.
Country	United States
Country code	US
CUSIP number	252828108
Earnings date	2026-11-09
Earnings time	amc
Employees	92
Employees change	14
Employees growth	17.95%
Enterprise value	$3.4B
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2015
In index	RUSSELL2000
Industry	Biotechnology
Is primary listing	Yes
Is SPAC	No
ISIN number	US2528281080
Last 10-K release date	2026-03-09
Last earnings date	2026-08-04
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$4.6B
Market cap category	Mid-Cap
Next earnings date	2026-11-09
Options	Yes
Price	$82.19
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	DNTH
U.S. state	New York
Website	https://dianthustx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-5%
EV/Sales	1,683.62x
FCF / EV yield	-4.86%
FCF yield	-3.54%
Forward EV/Sales	2,163.64x
Forward P/S	2,966.27x
P/B ratio	3.72x
P/S ratio	2,308.17x
Price / tangible book value	3.75x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross margin	100%
Operating margin	-11,441.39%
Pretax margin	-10,096.95%
Profit per employee	$-2.1M
Revenue per employee	$20,696
ROA	-17.69%
ROCE	-18.48%
ROE	-26.07%
ROIC	-18.43%
SBC / revenue	1,800%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth years	0
Gross profit growth	-60.77%
Gross profit growth (Q)	294.3%
Gross profit growth 3Y	-20.53%
Net income growth years	0
Revenue growth	-60.78%
Revenue growth (Q)	294.3%
Revenue growth (QoQ)	64.36%
Revenue growth 3Y	-20.53%
Revenue growth quarters	1
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-334,000
Depreciation and amortization	$123,000
EBIT	$-217.8M
EBITDA	$-217.7M
EPS	$-4.11
FCF per share	$-2.78
Financing cash flow	$1B
Free cash flow	$-155.7M
Free cash flow minus SBC	$-190M
Gross profit	$1.9M
Investing cash flow	$-776.6M
Net cash flow	$97.2M
Net income	$-192.2M
Operating cash flow minus SBC	$-189.6M
Operating income	$-217.8M
Revenue	$1.9M
Stock-based compensation	$34.3M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	35.67
Book value per share	$21.39
Debt / equity	0
Long-term assets	$315.7M
Long-term liabilities	$6.9M
Net cash (debt)	$1.2B
Net cash / market cap	27.06%
Net cash growth	286.39%
Net debt / equity	-1.01
Piotroski F-Score	2
Property, plant and equipment	$1.6M
Shareholders' equity	$1.2B
Tangible book value	$1.2B
Tangible book value per share	$21.39
Total assets	$1.2B
Total cash	$886.8M
Total debt	$1.3M
Total liabilities	$41.2M
WACC	5.24%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0
Current assets	$897.5M
Current liabilities	$34.4M
Current ratio	26.1
Net working capital	$-23.3M
Quick ratio	25.79
Working capital	$863.1M
Working capital turnover	0

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-32.34%
Dividend yield	0%
Shareholder yield	-32.34%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$93.27
1D price change	3.36%
1M price change	-9.42%
1M total return	-9.42%
1W price change	1.85%
1W total return	1.85%
1Y price change	139.29%
1Y return CAGR	139.43%
1Y total return	139.29%
20-day SMA	$80.30
200-day SMA	$84.65
3M price change	-23.24%
3M total return	-23.24%
3Y price change	574.03%
3Y return CAGR	88.87%
3Y total return	574.03%
50-day SMA	$93.88
50-day SMA vs 200-day SMA	50over200
52-week high	$117.88
52-week high date	2026-08-19
52-week low	$32.28
52-week low date	2025-11-03
6M price change	-7.97%
6M total return	-7.97%
All-time high	$117.88
All-time high date	2026-08-19
All-time low	$6.58
All-time low date	2023-12-19
Average true range (ATR)	$4.07
Average volume	922K
Beta (1Y)	-0.12
Beta (2Y)	0.89
Beta (5Y)	0.18
Change from 52-week high	-30.27%
Change from 52-week low	154.62%
Change from all-time high	-31.95%
Change from all-time low	1,119%
Change from open	5.04%
Day's gap	-1.6%
Dollar volume	$37.9M
High price	$82.21
Low price	$77.91
Monthly RSI	62.98
Open price	$78.25
Position in 52-week range	99.53%
Premarket change	-1.47%
Premarket close	$79.52
Premarket price	$78.35
Premarket volume	5.8K
Previous close	$79.52
Price vs 150-day SMA	-14%
Price vs 20-day SMA	-0.11%
Price vs 200-day SMA	-5.25%
Price vs 50-day SMA	-14.56%
Relative volume	0.5
RSI	41.67
Sharpe ratio	1.67
Sharpe ratio (3Y)	1.15
Sortino ratio	3.12
Sortino ratio (3Y)	2.05
Volume	461.5K
Weekly RSI	44.52
YTD price change	94.64%
YTD total return	94.64%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	55.9M
Float percentage	99.85%
Shares change (QoQ)	16.65%
Shares change (YoY)	32.34%
Shares held by insiders	0.15%
Shares held by institutions	125.54%
Shares outstanding	55.9M
Short % of float	16.09%
Short % of shares	16.07%
Short ratio	10.7 days

Deeper analysis on DNTH

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this DNTH report

Is a complete DNTH research report available?

No complete published report is available for Dianthus Therapeutics, Inc. (DNTH) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Dianthus Therapeutics, Inc. (DNTH)

Price

Financial snapshot

Fair-value bridge

Latest news · DNTH

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All DNTH indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on DNTH

Frequently asked questions